Escalon Medical Corp. (ESMC, Financial) filed Quarterly Report for the period ended 2012-09-30.
Escalon Medical Corporation has a market cap of $7.8 million; its shares were traded at around $0.96 with and P/S ratio of 0.3.
Consolidated product revenue from continuing operations decreased approximately $137,000 or 5.7%, to $2,270,000 during the three months ended September 30, 2012 as compared to same period of the last fiscal year. The decrease in revenue is attributed to a decrease in EMI s digital imaging cameras and AXIS image management systems offset by slight increase in Sonomed s ultrasound products.
Consolidated cost of goods sold from continuing operations totaled approximately $1,196,000, or 52.7%, of product revenue from continuing operations, for the three months ended September 30, 2012, as compared to $1,224,000, or 50.9%, of product revenue from continuing operations, for the same period of the prior fiscal year. The increase of 1.8% in cost of goods sold as a percentage of revenue is due mainly to the product mix sold during the current period.
Marketing, general and administrative expenses in the Sonomed-Escalon business segment increased $69,000, or 10%, to $753,000, as compared to the same period last fiscal year. The increase is due to an increase in sales people and related sales and marketing expenses and also an increase in business taxes.
Consolidated research and development expenses from continuing operations increased $44,000, or 20.0% of product revenue, to $264,000 during the three-month period ended September 30, 2012, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the planned introduction of new or enhanced products in the Sonomed-Escalon business units. The increase is related to increased engineering staff and related expenses necessary as Sonomed-Escalon researches and develops its next generation of diagnostic ultra-sound instruments.
Read the The complete Report
Escalon Medical Corporation has a market cap of $7.8 million; its shares were traded at around $0.96 with and P/S ratio of 0.3.
Highlight of Business Operations:
• Product revenue from continuing operations decreased approximately $137,000 or 5.7% during the three-month period ended September 30, 2012 as compared to the same period of last fiscal year. The decrease is related to sales decreasesConsolidated product revenue from continuing operations decreased approximately $137,000 or 5.7%, to $2,270,000 during the three months ended September 30, 2012 as compared to same period of the last fiscal year. The decrease in revenue is attributed to a decrease in EMI s digital imaging cameras and AXIS image management systems offset by slight increase in Sonomed s ultrasound products.
Consolidated cost of goods sold from continuing operations totaled approximately $1,196,000, or 52.7%, of product revenue from continuing operations, for the three months ended September 30, 2012, as compared to $1,224,000, or 50.9%, of product revenue from continuing operations, for the same period of the prior fiscal year. The increase of 1.8% in cost of goods sold as a percentage of revenue is due mainly to the product mix sold during the current period.
Marketing, general and administrative expenses in the Sonomed-Escalon business segment increased $69,000, or 10%, to $753,000, as compared to the same period last fiscal year. The increase is due to an increase in sales people and related sales and marketing expenses and also an increase in business taxes.
Consolidated research and development expenses from continuing operations increased $44,000, or 20.0% of product revenue, to $264,000 during the three-month period ended September 30, 2012, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the planned introduction of new or enhanced products in the Sonomed-Escalon business units. The increase is related to increased engineering staff and related expenses necessary as Sonomed-Escalon researches and develops its next generation of diagnostic ultra-sound instruments.
Read the The complete Report
